2016 - Fellow of the American Association for the Advancement of Science (AAAS)
2012 - Fellow of the American Academy of Arts and Sciences
2007 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
David T. Scadden mainly focuses on Stem cell, Cell biology, Haematopoiesis, Immunology and Progenitor cell. David T. Scadden interconnects Endothelial stem cell, Clinical uses of mesenchymal stem cells, Cellular differentiation, Adult stem cell and Bone marrow in the investigation of issues within Stem cell. His Cell biology research includes elements of Tissue homeostasis and In vivo.
His study in Haematopoiesis is interdisciplinary in nature, drawing from both Cell cycle, Cancer research, Homing and Cell growth. His Immunology research is multidisciplinary, relying on both Ex vivo and Genetic enhancement. David T. Scadden has included themes like Niche, Hematopoietic stem cell, Neuroscience and CXCR4 in his Progenitor cell study.
David T. Scadden mainly investigates Haematopoiesis, Stem cell, Cell biology, Immunology and Bone marrow. His Haematopoiesis research incorporates themes from Myeloid, Cancer research, Homing, Progenitor cell and Transplantation. His Stem cell study integrates concerns from other disciplines, such as Clinical uses of mesenchymal stem cells and Adult stem cell.
His Cell biology research is multidisciplinary, incorporating perspectives in Endothelial stem cell, Cell, Cellular differentiation and Niche. His research integrates issues of Acquired immunodeficiency syndrome and Virology in his study of Immunology. His work carried out in the field of Bone marrow brings together such families of science as Stromal cell, Mesenchymal stem cell and Endocrinology.
David T. Scadden focuses on Haematopoiesis, Bone marrow, Cancer research, Cell biology and Stem cell. In his work, Cell fate determination is strongly intertwined with Progenitor cell, which is a subfield of Haematopoiesis. His Bone marrow study contributes to a more complete understanding of Immunology.
The various areas that he examines in his Cancer research study include Cancer, Leukemia and Mesenchymal stem cell. His Cell biology study combines topics in areas such as Endothelial stem cell, Chromatin, Epigenetics and Cell growth. His work on Hematopoietic stem cell, Stem cell factor and Hematopoietic Stem Cell Mobilization as part of general Stem cell research is frequently linked to Mobilization, bridging the gap between disciplines.
His main research concerns Bone marrow, Haematopoiesis, Progenitor cell, Cell biology and Stem cell. His Bone marrow research incorporates elements of Lymphopoiesis, Hematology and Cellular differentiation. His studies in Haematopoiesis integrate themes in fields like Niche, Cancer research, Regeneration, Mesenchymal stem cell and Transplantation.
His research in Progenitor cell intersects with topics in T cell, Cell fate determination and Bioinformatics. His Cell biology study incorporates themes from Endothelial stem cell, Cell, Genetics and Congenic. Stem cell is closely attributed to Osteoblast in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Osteoblastic cells regulate the haematopoietic stem cell niche
Laura M Calvi;Gregor B Adams;K. W. Weibrecht;Jonathan Weber.
Nature (2003)
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
Simón Méndez-Ferrer;Tatyana V. Michurina;Francesca Ferraro;Amin R. Mazloom.
Nature (2010)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda.
Nature Medicine (2004)
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells.
Maïté Lewin;Nadia Carlesso;Ching Hsuan Tung;Xiao Wu Tang.
Nature Biotechnology (2000)
The stem-cell niche as an entity of action
David T. Scadden.
Nature (2006)
The bone marrow niche for haematopoietic stem cells
Sean J. Morrison;David T. Scadden.
Nature (2014)
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Tracy T. Batchelor;A. Gregory Sorensen;A. Gregory Sorensen;Emmanuelle di Tomaso;Wei Ting Zhang;Wei Ting Zhang.
Cancer Cell (2007)
Hematopoietic stem cell quiescence maintained by p21cip1/waf1.
Tao Cheng;Neil Rodrigues;Hongmei Shen;Yong-guang Yang.
Science (2000)
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a.
Viktor Janzen;Randolf Forkert;Heather E. Fleming;Yoriko Saito.
Nature (2006)
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Marc H. G. P. Raaijmakers;Siddhartha Mukherjee;Shangqin Guo;Siyi Zhang.
Nature (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Royal Brisbane and Women's Hospital
Beth Israel Deaconess Medical Center
Harvard University
Harvard University
Harvard University
Harvard University
Harvard University
Harvard University
Broad Institute
Harvard University
The University of Texas at Austin
Pondicherry University
Macquarie University
University of California, San Diego
City University of Hong Kong
Chinese Academy of Sciences
Peter MacCallum Cancer Centre
Spanish National Research Council
North Carolina State University
Jawaharlal Nehru University
Scripps Research Institute
Curtin University
Centre national de la recherche scientifique, CNRS
Zhejiang University
Harvard University
Lawrence Berkeley National Laboratory